Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

 

 

For the Years Ended December 31,

(in CHF ‘000 except for share and per share data)

2018

2017

2016

2015

2014
Earnings / (Loss) per share in CHF (basic)(1)(2) (0.82) (0.46) (0.14) 0.47 0.25
Earnings / (Loss) per share in CHF (fully diluted)(2) (0.82) (0.46) (0.14) 0.44 0.24
Weighted-average number of shares used to compute earnings per share basic 61,838,228 57,084,295 50,096,859 43,412,250 42,684,750

Weighted-average number of shares used to compute earnings per share fully diluted

61,838,228 57,084,295 50,096,859 46,043,198 45,552,500

 

(1)For the periods prior to the closing of our initial public offering on September 23, 2016, earnings per share includes preferred shares outstanding. These preferred shares were converted on a one-for-one basis upon closing of our initial public offering on September 23, 2016. Amounts for fiscal years 2015 and 2014 have also been adjusted for the 250-for-1 stock split effective October 23, 2015.

 

(2)Earnings per share calculations do not give effect to the Series E Private Placement Extension or the CS AG Share Issuance effected in 2016.

 

 

As of December 31,

 
 

2018

2017

2016

2015

2014
(in CHF thousands)  
Cash and cash equivalents 156,462 124,377 152,210 76,522 3,306
Short-term financial assets 30,000
Total assets 196,556 132,013 156,100 79,931 30,296
Accumulated losses (121,877) (72,607) (46,921) (40,381) (60,455)
Total shareholder’s equity 177,623 116,839 142,380 71,043 23,467
Total shareholder’s equity and liabilities 196,556 132,013 156,100 79,931 30,296
Share capital 1,351 1,147 1,135 928 854

 

B.Capitalization and indebtedness

 

Not applicable.

 

C.Reasons for the offer and use of proceeds

 

Not applicable.

 

D.Risk factors

 

You should carefully consider the risks and uncertainties described below and the other information in this Annual Report before making an investment in our common shares. Our business, financial condition or results of operations could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common shares could decline and you could lose all or part of your investment. This Annual Report also contains forward-looking statements that involve risks and uncertainties. See “Forward-Looking Statements.” Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors.

 

Risks Related to Our Business

 

We depend heavily on the success of our clinical and, to a lesser extent, pre-clinical products. Our clinical product candidates include crenezumab, anti-Tau antibody, ACI-24 for Alzheimer’s disease, or AD, ACI-24 for Down syndrome, or DS, ACI-35, Morphomer Tau and Tau-PET Imaging tracer. If our clinical studies are unsuccessful, we or our collaboration partners do not obtain regulatory approval or we or our collaboration partners are unable to commercialize crenezumab, anti-Tau antibody, ACI-24 for AD and DS, ACI-35, Morphomer Tau and Tau-PET Imaging tracer, or we experience significant delays in doing so, our business, financial condition and results of operations will be materially adversely affected.

 

 4


© AC Immune 2015